NEOT -70% on failed phase-2 in “double-chin” fat: https://finance.yahoo.com/news/neothetics-announces-top-line-results-120000776.html Neothetics…today announced top-line safety and efficacy results from its Phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. LIPO-202 did not demonstrate improvement on any efficacy measurements or separation from placebo. LIPO-202 continued to show a benign safety profile. ‘rkrw’ and I disparaged this company’s prospects at the time of the IPO (#msg-108341768, #msg-108345338).